View Financial HealthSilva Pharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6Silva Pharmaceuticals 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).공시 • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).공시 • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026공시 • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026공시 • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025공시 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh공시 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025공시 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025공시 • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m).공시 • Nov 09Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m).Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.공시 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, BangladeshNew Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m).공시 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.공시 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024Reported Earnings • Feb 03Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023)Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings.공시 • Jan 24Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).공시 • Nov 07Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023공시 • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.공시 • Oct 30Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time.공시 • Oct 20Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023Reported Earnings • May 17Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses.Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years.Reported Earnings • Feb 09Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year.Reported Earnings • Feb 03Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue.공시 • Jul 17Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SILVAPHL 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SILVAPHL 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Silva Pharmaceuticals 배당 수익률 vs 시장SILVAPHL의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SILVAPHL)0%시장 하위 25% (BD)0.8%시장 상위 25% (BD)3.5%업계 평균 (Pharmaceuticals)3.6%분석가 예측 (SILVAPHL) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SILVAPHL 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SILVAPHL 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: SILVAPHL BD 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: SILVAPHL 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YBD 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 06:21종가2026/06/29 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Silva Pharmaceuticals Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
공시 • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
공시 • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.
Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026
공시 • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
공시 • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025
공시 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
공시 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025
공시 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025
공시 • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m).
공시 • Nov 09Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m).
Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.
공시 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m).
공시 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
공시 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024
Reported Earnings • Feb 03Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023)Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
공시 • Jan 24Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
공시 • Nov 07Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023
공시 • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.
공시 • Oct 30Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time.
공시 • Oct 20Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023
Reported Earnings • May 17Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses.
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years.
Reported Earnings • Feb 09Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year.
Reported Earnings • Feb 03Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue.
공시 • Jul 17Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020